ReviewFrontiers in oncology2020
Toward Systems Biomarkers of Response to Immune Checkpoint Blockers.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Peripheral SNCADiscover oncology · 2025Article
- IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer.Journal of translational medicine · 2025Article
- Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data.NPJ precision oncology · 2025Article
- Mathematically mapping the network of cells in the tumor microenvironment.Cell reports methods · 2025Article
- Integrating histopathology and transcriptomics for spatial tumor microenvironment profiling in a melanoma case study.NPJ precision oncology · 2024Article
- Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.Frontiers in immunology · 2024Review
- Identification of memory B-cell-associated miRNA signature to establish a prognostic model in gastric adenocarcinoma.Journal of translational medicine · 2023Article
- Proteome deconvolution of liver biopsies reveals hepatic cell composition as an important marker of fibrosis.Computational and structural biotechnology journal · 2023Article
- Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.The oncologist · 2022Article
- IgD ligation allows peritoneal cavity B cell proliferation.Immunobiology · 2022Article
- Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage.Molecular oncology · 2021Article
- Interpretable systems biomarkers predict response to immune-checkpoint inhibitors.Patterns (New York, N.Y.) · 2021Article
- The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development.OncoTargets and therapy · 2021Review
- Overall Survival in Heart Disease-Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study.Frontiers in oncology · 2020Article
- Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy with checkpoint blockers (ICBs), aimed at unleashing the immune response toward tumor cells, has shown a great improvement in overall patient survival compared to standard therapy, but only in a subset of patients. While a number of recent studies have significantly improved our understanding of mechanisms playing an important role in the tumor microenvironment (TME), we still have an incomplete view of how the TME works as a whole. This hampers our ability to effectively predict the large heterogeneity of patients' response to ICBs. Systems approaches could overcome this limitation by adopting a holistic perspective to analyze the complexity of tumors. In this Mini Review, we focus on how an integrative view of the increasingly available multi-omics experimental data and computational approaches enables the definition of new systems-based predictive biomarkers. In particular, we will focus on three facets of the TME toward the definition of new systems biomarkers. First, we will review how different types of immune cells influence the efficacy of ICBs, not only in terms of their quantification, but also considering their localization and functional state. Second, we will focus on how different cells in the TME interact, analyzing how inter- and intra-cellular networks play an important role in shaping the immune response and are responsible for resistance to immunotherapy. Finally, we will describe the potential of looking at these networks as dynamic systems and how mathematical models can be used to study the rewiring of the complex interactions taking place in the TME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.